Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Hypertension Clinical Trial

Official title:

Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06055452
• Other study ID #: 2023-GSP-GG-18
• Status: Recruiting
• Phase: Phase 4
• Start date: January 19, 2024
• Est. completion date: December 31, 2024

Study information

• Verified date: April 2024
• Source: China National Center for Cardiovascular Diseases
• Contact: Xin Zheng, MD,PhD
• Phone: +86 13681077247
• Email: zhengxin[@]fuwai.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.

Description:

Hypertension is the leading risk factor of heart failure with preserved heart failure. The overall control rate is about 16% in China. Given the large amounts of hypertensive patients at pre-heart failure (stage B), it's critical to explore the effect of additional cardioprotective medication in addition to well-controlled blood pressure. Sodium-glucose cotransporter-2 inhibitors (engagliflozin) have been shown to improve cardiac function or prognosis in patients with diabetes or heart failure. However, whether it has a cardioprotective effect on hypertensive patients with pre-heart failure and without diabetes remains unknown. We will conduct a multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes. We will enroll 120 eligible patients randomized to receive a placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. The secondary endpoints include echocardiography or magnetic resonance imaging to measure structural and functional parameters, blood pressure, glucose, and blood biomarkers of inflammation and fibrosis. We sought to comprehensively evaluate the effect of empagliflozin on the structure and function and explore the underlying mechanisms to provide insights and evidence for the prevention of heart failure in hypertensive patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 31, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Meeting all the following criteria:

1. Aged 40 and above; less than 75 years.

2. Hypertensive patients currently taking at least one antihypertensive medication as recommended by guidelines, and blood pressure is within the target range (<140/90 mmHg).

3. The left atrial volume index measured by transthoracic echocardiography exceeds 34 mL/m², or the ratio of the average E/e' >9 and left atrial volume index >= 29 mL/m² measured by transthoracic echocardiography.

4. Signing an informed consent form.

Exclusion Criteria:

• • Exclusion criteria include any of the following conditions:

1. History of diabetes.

2. History of heart failure.

3. History of coronary artery disease.

4. Left ventricular systolic dysfunction, defined as LVEF < 50%.

5. Systolic blood pressure < 100 mmHg.

6. A history of arrhythmias such as atrial fibrillation, atrial flutter, frequent atrial premature contractions, and frequent ventricular premature contractions may impact the structural and functional aspects of the heart.

7. Moderate and above valvular heart disease.

8. Severe obstructive disease of the left ventricular outflow tract, including aortic valve stenosis.

9. Visited within the past 1 month due to Genitourinary tract infection.

10. Chronic kidney disease or estimated Glomerular Filtration Rate (eGFR) < 45 ml/min/1.73m².

11. Alanine aminotransferase or aspartate aminotransferase levels > 3 times the upper limit of normal.

12. Contraindications to taking SGLT2 inhibitors.

13. Currently taking SGLT2 inhibitors, SGLT-1/2 inhibitors, or other antihyperglycemic medications (including metformin, glucagon-like peptide-1 receptor agonists, etc.).

14. Pregnancy or planning pregnant, or currently breastfeeding.

15. Malignant tumors or other severe illnesses with a life expectancy of less than 3 years.

16. History of alcohol abuse or substance abuse within the past year.

17. Mental disorders or communication barriers, cognitive impairments, or other severe illnesses that may affect participation in the study.

18. Participation in or currently participating in other clinical trials within the last 3 months.

19. Known poor compliance with study follow-up or study drug.

20. Any condition or contraindication that makes a person intolerant to magnetic resonance imaging (MRI) or contraindicates MRI examination, such as the presence of implanted intracranial aneurysm clips, cardiac pacemakers or defibrillators, insulin pumps, etc.

Related Conditions & MeSH terms

• Heart Failure
• Hypertension

Intervention

Drug:
• Empagliflozin 10 MG
Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
• Placebo
Each participant in the placebo group takes matching placebo.

Locations

Country	Name	City	State
China	Fuwai Hospital, Chinese Academy of Medical Sciences	Beijing	Beijing
China	Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of left atrial volume index	Changes in Left Atrial Volume Index (LAVI, mL/m2) as measured by MRI from baseline to 6 months.	6 months
Secondary	Change of cardiac structure and functional	Left ventricular functional indicators: Echocardiography/Magnetic Resonance Imaging measured Left Ventricular Ejection Fraction (LVEF, %), the ratio of early mitral inflow velocity to early diastolic mitral annular velocity (E/e', cm/s), and Global Longitudinal Strain (GLS, %).; Left ventricular structural indicators: Echocardiography/Magnetic Resonance Imaging measured Left Ventricular Mass Index (LVMI, g/m2).; Left atrial functional indicators: Echocardiography/Magnetic Resonance Imaging measured Left Atrial Ejection Fraction (LAEF, %) and echocardiography measured Left Atrial Volume Index (LAVI, mL/m2).	6 months
Secondary	Biomarkers	Biomarker concentrations were measured as follows: NT-pro BNP in picograms per milliliter (pg/mL).; Cardiac Troponin I in nanograms per milliliter (ng/mL).; Cardiac Fibrosis Biomarkers, including Collagen type I alpha 1 (Col1A1) in nanograms per milliliter, Matrix Metalloproteinases (MMP-2, MMP-3, MMP-4) in picograms per milliliter (pg/mL) and soluble ST2 protein (sST-2) in nanograms per milliliter (ng/mL).; Inflammation Biomarkers, including High-sensitivity C-reactive protein (hs-CRP) in milligrams per liter (mg/L) and Interleukin-6 (IL-6), Interleukin-1ß (IL-1ß), and Galectin-3 (Gal-3) in picograms per milliliter (pg/mL).	6 months
Secondary	Estimated Glomerular Filtration Rate (eGFR)	Change of eGFR	6 months